Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs